Epidemiology of Antiretroviral Multiclass Resistance (Q57259606)

1

0 references

P. R. Harrigan

2

0 references

M. Senecal

3

0 references

B. Yip

4

0 references

E. Druyts

5

0 references

J. S. G. Montaner

American Journal of Epidemiology

7

0 references

language of work or name

English

0 references

publication date

28 July 2010

0 references

published in

0 references

volume

172

0 references

issue

4

0 references

page(s)

460-468

0 references

cites work

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

An update on HIV-1 antiretroviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Pharmacogenetics of antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWQ101